SJ Medical
SJ Medical
The global PTCA Dilatation Catheter industry is witnessing an unprecedented surge, driven by the increasing prevalence of cardiovascular diseases (CVD) and the shift toward minimally invasive surgical techniques. As a critical component in Percutaneous Coronary Intervention (PCI), the PTCA balloon catheter has evolved from simple dilation tools to sophisticated, high-engineered devices capable of navigating complex arterial tortuosity.
Technological advancements such as Drug-Coated Balloons (DCB), High-Pressure Non-Compliant (NC) balloons, and ultra-low profile crossing diameters have redefined clinical outcomes. In 2024, the market focus has shifted toward "Functional Interventionalism," where catheters are not just opening vessels but delivering therapeutic agents or preparing lesions for stent optimization.
Global procurement trends indicate a strong demand for reliability and cost-effectiveness. While European and American markets traditionally dominated the high-end segment, Chinese medical manufacturers like Hangzhou SJ Medical have bridged the gap, offering CE-certified, world-class performance at competitive industrial scales.
Global Market Size
Annual CAGR
Established in 2015, Hangzhou SJ Medical is a premier high-tech enterprise dedicated to the research, development, manufacturing, and commercialization of vascular interventional medical devices. We focus on both cardiovascular and peripheral intervention fields, striving to provide safe, reliable, and innovative solutions for healthcare providers worldwide.
Over the years, SJ Medical has developed a comprehensive product portfolio covering key areas of vascular intervention. Its offerings span from various types of balloon catheters for coronary and peripheral applications to supporting access and diagnostic devices, as well as advanced stent systems. Through continuous innovation and strong R&D capabilities, the company has obtained multiple patents and international certifications, laying a solid foundation for sustainable growth in both domestic and global markets.
SJ Medical operates a modern manufacturing facility of 5,000 square meters built to GMP standards. We utilize a million-class clean workshop with localized hundred-class areas for critical high-precision processes.
Our technical team consists of industry veterans with decades of experience in medical device R&D. Under senior leadership, we maintain strict quality control and continuous process improvement.
Equipped with advanced balloon forming systems, laser welding, and high-spec marking technologies, ensuring product consistency and reliability for complex surgical needs.
In modern cardiology departments from Jakarta to Berlin, the PTCA Dilatation Catheter is indispensable. It is used for Pre-dilatation of stenotic lesions, Post-dilatation of stents (using NC balloons), and crossing calcified arteries. Peripheral applications include renal artery angioplasty and limb salvage procedures in diabetic patients.
Global buyers prioritize three factors: Trackability (navigation through vessels), Crossability (passing through tight lesions), and Pushability (transmission of force). Our catheters are engineered with hydrophilic coatings and low-profile tips to meet these rigorous clinical demands.
The industry is moving toward "Smart Intervention." While our catheters remain physical tools, our R&D is exploring compatibility with AI-driven imaging systems to optimize balloon sizing and pressure delivery, reducing the risk of vessel dissection.
SJ Medical strictly adheres to international quality standards. We hold CE Certification, ISO 13485, and CFDA approvals. This commitment to quality has enabled us to export to over 20 countries, including:
Our factory provides full OEM/ODM services, supporting global distributors in localized market penetration with high-quality, China-manufactured interventional devices.
100% Inspection Rate
GMP Compliant
Advanced R&D Lab
Since Andreas Gruentzig performed the first coronary angioplasty in 1977, the Dilatation Catheter has undergone revolutionary changes. At Hangzhou SJ Medical, we honor this legacy by integrating the latest material science into our production. Modern PTCA catheters require a delicate balance of stiffness in the proximal shaft for pushability and extreme flexibility in the distal tip for atraumatic navigation. Our use of Pebax and specialized Nylon blends allows our balloons to achieve "Non-Compliant" (NC) characteristics—essential for high-pressure stent expansion without the "dog-bone" effect that can damage healthy vessel walls.
Cardiovascular disease remains the leading cause of mortality globally. In emerging markets, there is an urgent need for high-quality medical devices that do not compromise on safety despite budget constraints. SJ Medical’s mission is to democratize high-end interventional technology. By optimizing our manufacturing chain in China, we reduce the "medical premium" typically charged by Western giants, making life-saving procedures more accessible in regions like Southeast Asia, Latin America, and Africa.
Beyond the heart, peripheral artery disease (PAD) is a growing concern, especially with the global rise in diabetes. Our PTA Balloon Dilatation Catheters are specifically designed for the larger vessels of the legs and kidneys. These devices require higher burst pressures and larger balloon diameters. Our spiral balloon technology ensures uniform expansion even in long, diffuse lesions typical of the femoral arteries.
Trust in medical manufacturing is built through transparency. Every batch of SJ Medical catheters undergoes a series of rigorous tests: Leakage testing, Burst pressure testing (RBP), Fatigue testing (multiple inflations), and Coating integrity analysis. Our million-class cleanrooms are monitored 24/7 for particulate matter and microbial levels, ensuring that every product reaching a catheterization lab (Cath Lab) is sterile and safe.
The medical device industry is increasingly looking toward sustainability. SJ Medical is exploring bio-compatible materials and streamlined packaging to reduce waste. Furthermore, our R&D is focusing on the next generation of Drug-Eluting Balloons (DEB), which leave no permanent metal behind in the vessel, a significant trend in treating "In-Stent Restenosis" (ISR).
